Levetiracetam Prophylaxis in Pediatric Migraine—An Open-Label Study

Authors

  • Ann Pakalnis MD,

  • Donna Kring MS, CNP,

  • Lisa Meier RN


  • From the Department of Neurology, Children's Hospital, Columbus, OH, USA.

Address all correspondence to Dr. Ann Pakalnis, Children's Hospital—Neurology, 700 Children's Drive, Columbus, OH 43205, USA.

Abstract

Background.—Migraine is common in the pediatric population. Levetiracetam, an anti-epileptic drug, has shown some efficacy in small prospective adult headache studies.

Methods.—We prospectively evaluated levetiracetam in an open-label study in 20 pediatric migraine patients to assess tolerability and efficacy.

Results.—Eighteen of 20 patients had significant reduction in headache frequency. PedMIDAS showed significant decrease in disability scores, side effects were minimal (mild behavioral changes).

Conclusion.—Levetiracetam had some efficacy in reducing migraine frequency and disability. Further larger studies are warranted, possibly utilizing a placebo-controlled design.

Ancillary